125
Participants
Start Date
October 1, 2013
Primary Completion Date
July 10, 2020
Study Completion Date
July 10, 2020
RO7490677
IV infusion
Ruxolitinib
IV infusion
Mount Sinai Medical Center, New York
Weill Cornell Medical Center, New York
University of Maryland Medical Center, Baltimore
Fondazione IRCCS Policlinico San Matteo, Pavia
Wake Forest Baptist Medical Center, Winston-Salem
Emory Hospital, Atlanta
Johannes Wesling Academic Medical Center, Minden
Vanderbilt University Medical Center, Nashville
Marche Nord Hospital, Pesaro
Hospital Saint-Louis, Paris
MD Anderson Cancer Center, Houston
Mayo Clinic Cancer Center, Phoenix
Hadassah Medical Centre, Jerusalem
Stanford Cancer Institute, Palo Alto
Meir Medical Centre, Kfar Saba
Dana-Farber Cancer Institute, Boston
University of Michigan, Ann Arbor
Providence Health Care, Vancouver
The Princess Margaret Cancer Centre, Toronto
University Medical Center RWTH Aachen, Aachen
Erasmus Medical Center, Rotterdam
Radboud University Medical Center, Nijmegen
Guy's and St. Thomas' Hospital, London
Hoffmann-La Roche
INDUSTRY